全文获取类型
| 收费全文 | 9681篇 |
| 免费 | 941篇 |
| 国内免费 | 22篇 |
专业分类
| 耳鼻咽喉 | 70篇 |
| 儿科学 | 378篇 |
| 妇产科学 | 333篇 |
| 基础医学 | 1392篇 |
| 口腔科学 | 159篇 |
| 临床医学 | 1268篇 |
| 内科学 | 1789篇 |
| 皮肤病学 | 172篇 |
| 神经病学 | 981篇 |
| 特种医学 | 235篇 |
| 外科学 | 934篇 |
| 综合类 | 200篇 |
| 一般理论 | 24篇 |
| 预防医学 | 1123篇 |
| 眼科学 | 284篇 |
| 药学 | 645篇 |
| 中国医学 | 10篇 |
| 肿瘤学 | 647篇 |
出版年
| 2023年 | 83篇 |
| 2022年 | 46篇 |
| 2021年 | 205篇 |
| 2020年 | 197篇 |
| 2019年 | 233篇 |
| 2018年 | 235篇 |
| 2017年 | 213篇 |
| 2016年 | 200篇 |
| 2015年 | 230篇 |
| 2014年 | 359篇 |
| 2013年 | 481篇 |
| 2012年 | 682篇 |
| 2011年 | 614篇 |
| 2010年 | 369篇 |
| 2009年 | 325篇 |
| 2008年 | 603篇 |
| 2007年 | 593篇 |
| 2006年 | 569篇 |
| 2005年 | 586篇 |
| 2004年 | 536篇 |
| 2003年 | 441篇 |
| 2002年 | 429篇 |
| 2001年 | 148篇 |
| 2000年 | 162篇 |
| 1999年 | 156篇 |
| 1998年 | 102篇 |
| 1997年 | 90篇 |
| 1996年 | 85篇 |
| 1995年 | 74篇 |
| 1994年 | 76篇 |
| 1993年 | 72篇 |
| 1992年 | 106篇 |
| 1991年 | 90篇 |
| 1990年 | 94篇 |
| 1989年 | 75篇 |
| 1988年 | 99篇 |
| 1987年 | 92篇 |
| 1986年 | 72篇 |
| 1985年 | 80篇 |
| 1984年 | 73篇 |
| 1983年 | 75篇 |
| 1982年 | 45篇 |
| 1981年 | 40篇 |
| 1980年 | 36篇 |
| 1979年 | 42篇 |
| 1978年 | 48篇 |
| 1977年 | 35篇 |
| 1973年 | 38篇 |
| 1972年 | 34篇 |
| 1970年 | 34篇 |
排序方式： 共有10000条查询结果，搜索用时 312 毫秒
1.
2.
3.
Sebastian P. Mondaca MD Dazhi Liu PharmD BCOP Jessica R. Flynn Sandy Badson Stefan Hamaway BS Mrinal M. Gounder MD Danny N. Khalil MD PhD Alexander E. Drilon MD Bob T. Li MD MPH Komal L. Jhaveri MD Alison M. Schram MD Katherine E. Kargus RN Mary Kate Kasler DNP MSN Natalie M. Blauvelt Neil H. Segal MD PhD Marinela Capanu PhD Margaret K. Callahan MD PhD David M. Hyman MD Maya Gambarin-Gelwan MD James J. Harding MD 《Cancer》2020,126(22):4967-4974
4.
Stefaniuk Catherine M. Schlegelmilch June Meyerson Howard J. Harding Clifford V. Maitta Robert W. 《Journal of thrombosis and thrombolysis》2022,53(4):950-953
Journal of Thrombosis and Thrombolysis - Over the last few years data from our group have indicated that α-synuclein is important in development of immune cells as well as potentially... 相似文献
5.
6.
7.
K. A. Harding M. E. Pushpanathan S. R. Whitworth S. Nanthakumar R. S. Bucks T. C. Skinner 《Diabetic medicine》2019,36(12):1600-1611
8.
9.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献10.